Association of Cardiometabolic Index with Mortality Risk in Early-Stage Cardiovascular-Kidney-Metabolic Syndrome and Its Potential Role in Metabolically Unhealthy Phenotypes: Evidence from NHANES 2007-2018.
Haoyu Liu, Yunhui Chen, Xue Yang, Tianqi Pan, Shouyan Wang
{"title":"Association of Cardiometabolic Index with Mortality Risk in Early-Stage Cardiovascular-Kidney-Metabolic Syndrome and Its Potential Role in Metabolically Unhealthy Phenotypes: Evidence from NHANES 2007-2018.","authors":"Haoyu Liu, Yunhui Chen, Xue Yang, Tianqi Pan, Shouyan Wang","doi":"10.1177/15578518261423748","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The cardiometabolic index (CMI) has emerged as a composite marker of metabolic dysfunction. However, its prognostic value for mortality in early-stage cardiovascular-kidney-metabolic (CKM) syndrome remains unclear. This study aimed to evaluate the association between CMI and mortality risk in individuals with CKM stages 0-3, and to assess whether CMI provides incremental predictive value over body mass index (BMI).</p><p><strong>Methods: </strong>This retrospective cohort study included 11,280 adults from the National Health and Nutrition Examination Survey 2007-2018 with CKM stages 0-3. CMI was calculated as (triglycerides/HDL-C) × waist-to-height ratio. Mortality outcomes were ascertained through linkage with the National Death Index through December 31, 2019. Survey-weighted Cox proportional hazards regression and restricted cubic splines were used to examine associations. Kaplan-Meier survival curves with log-rank tests were employed to compare survival probabilities across CMI-BMI discordance phenotypes. Random survival forest models compared the predictive performance of CMI versus BMI.</p><p><strong>Results: </strong>During a median follow-up of 6.2 years, 623 all-cause deaths and 159 cardiovascular deaths occurred. In fully adjusted models, participants in the highest CMI quartile had significantly elevated risks of all-cause mortality [hazard ratio (HR) = 1.55, 95% confidence intervals (CI): 1.15-2.09] and cardiovascular mortality (HR = 1.91, 95% CI: 1.05-3.46) compared with the lowest quartile. Restricted cubic spline analyses revealed significant nonlinear associations, with inflection points at CMI of 2.51 for all-cause mortality and 1.06 for cardiovascular mortality. In the overweight subgroup and among diabetic patients, CMI demonstrated superior risk stratification compared with BMI. Notably, metabolically obese normal-weight individuals exhibited significantly worse survival than metabolically healthy obese individuals.</p><p><strong>Conclusions: </strong>CMI is independently associated with all-cause and cardiovascular mortality in early-stage CKM syndrome, with evidence of threshold effects. CMI may serve as a valuable complementary tool to BMI for identifying high-risk individuals, particularly among those with metabolically unhealthy phenotypes masked by normal weight status.</p>","PeriodicalId":18405,"journal":{"name":"Metabolic syndrome and related disorders","volume":" ","pages":"148-158"},"PeriodicalIF":1.6000,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Metabolic syndrome and related disorders","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/15578518261423748","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/2/14 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
Abstract
Background: The cardiometabolic index (CMI) has emerged as a composite marker of metabolic dysfunction. However, its prognostic value for mortality in early-stage cardiovascular-kidney-metabolic (CKM) syndrome remains unclear. This study aimed to evaluate the association between CMI and mortality risk in individuals with CKM stages 0-3, and to assess whether CMI provides incremental predictive value over body mass index (BMI).
Methods: This retrospective cohort study included 11,280 adults from the National Health and Nutrition Examination Survey 2007-2018 with CKM stages 0-3. CMI was calculated as (triglycerides/HDL-C) × waist-to-height ratio. Mortality outcomes were ascertained through linkage with the National Death Index through December 31, 2019. Survey-weighted Cox proportional hazards regression and restricted cubic splines were used to examine associations. Kaplan-Meier survival curves with log-rank tests were employed to compare survival probabilities across CMI-BMI discordance phenotypes. Random survival forest models compared the predictive performance of CMI versus BMI.
Results: During a median follow-up of 6.2 years, 623 all-cause deaths and 159 cardiovascular deaths occurred. In fully adjusted models, participants in the highest CMI quartile had significantly elevated risks of all-cause mortality [hazard ratio (HR) = 1.55, 95% confidence intervals (CI): 1.15-2.09] and cardiovascular mortality (HR = 1.91, 95% CI: 1.05-3.46) compared with the lowest quartile. Restricted cubic spline analyses revealed significant nonlinear associations, with inflection points at CMI of 2.51 for all-cause mortality and 1.06 for cardiovascular mortality. In the overweight subgroup and among diabetic patients, CMI demonstrated superior risk stratification compared with BMI. Notably, metabolically obese normal-weight individuals exhibited significantly worse survival than metabolically healthy obese individuals.
Conclusions: CMI is independently associated with all-cause and cardiovascular mortality in early-stage CKM syndrome, with evidence of threshold effects. CMI may serve as a valuable complementary tool to BMI for identifying high-risk individuals, particularly among those with metabolically unhealthy phenotypes masked by normal weight status.
期刊介绍:
Metabolic Syndrome and Related Disorders is the only peer-reviewed journal focusing solely on the pathophysiology, recognition, and treatment of this major health condition. The Journal meets the imperative for comprehensive research, data, and commentary on metabolic disorder as a suspected precursor to a wide range of diseases, including type 2 diabetes, cardiovascular disease, stroke, cancer, polycystic ovary syndrome, gout, and asthma.
Metabolic Syndrome and Related Disorders coverage includes:
-Insulin resistance-
Central obesity-
Glucose intolerance-
Dyslipidemia with elevated triglycerides-
Low HDL-cholesterol-
Microalbuminuria-
Predominance of small dense LDL-cholesterol particles-
Hypertension-
Endothelial dysfunction-
Oxidative stress-
Inflammation-
Related disorders of polycystic ovarian syndrome, fatty liver disease (NASH), and gout